The EU approved an antibiotic for treating urinary tract infections

European regulators have approved the use of epidermal (cefiderocol), an antibiotic developed for the treatment of complicated urinary tract infections in adult patients. The drug can be used in infections caused by gram-negative bacteria, therapeutic options which are limited, PharmaTimes writes.

This drug is already approved in the United States, and the results of clinical trials confirm its efficacy and favorable safety profile. According to the KEY held with the participation of 448 patients, the use of a new drug provided a recovery of 72.6% of patients 7 days after completion of treatment, whereas in the control group, the use of alternative antibiotics after a week of therapy recovered only 54,6% of patients. The most common adverse events of epidermal had diarrhea, constipation, nausea, vomiting, reactions at the injection site and some others.

Currently, a major concern of the medical community is causing the spread of drug resistance of bacteria, so to market a new antibiotic is a major event.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]